| Literature DB >> 21349180 |
Manfred Weidmann1, Amadou A Sall, Jean-Claude Manuguerra, Lamine Koivogui, Aime Adjami, Faye Fatou Traoré, Kjell-Olof Hedlund, Gunnel Lindegren, Ali Mirazimi.
Abstract
Information on the replication of viral haemorrhagic fever viruses is not readily available and has never been analysed in a comparative approach. Here, we compared the cell culture growth characteristics of haemorrhagic fever viruses (HFV), of the Arenaviridae, Filoviridae, Bunyaviridae, and Flavivridae virus families by performing quantitative analysis of cell culture supernatants by (i) electron microscopy for the quantification of virus particles, (ii) quantitative real time PCR for the quantification of genomes, and (iii) determination of focus forming units by coating fluorescent antibodies to infected cell monolayers for the quantification of virus infectivity.The comparative analysis revealed that filovirus and RVFV replication results in a surplus of genomes but varying degrees of packaging efficiency and infectious particles. More efficient replication and packaging was observed for Lassa virus, and Dengue virus resulting in a better yield of infectious particles while, YFV turned out to be most efficient with only 4 particles inducing one FFU. For Crimean-Congo haemorrhagic fever virus (CCHFV) a surplus of empty shells was observed with only one in 24 particles equipped with a genome. The complete particles turned out to be extraordinarily infectious.Entities:
Mesh:
Year: 2011 PMID: 21349180 PMCID: PMC3056813 DOI: 10.1186/1743-422X-8-81
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Description of antibodies used for determination of FFU
| Virus | Primary antibodies | Secondary antibodies |
|---|---|---|
| LASV | Mouse serum Anti-Lassa virus (NP), (in-house) | FITC-conjugated Rabbit Anti-Mouse Immunoglobulins, (DAKO Cytomation, Denmark) |
| EBOZV/EBOSV | Mouse serum Anti-Ebola virus (NP), (in-house) | FITC-conjugated Goat Anti-Mouse IgG, (Jackson ImmunoResearch, Baltimore, USA) |
| MARV | Human patient serum | FITC-conjugated Goat Anti-Human IgG (FC specific), (Sigma-Aldrich Ltd., UK) |
| CCHFV | Rabbit serum Anti-CCHFV (NP), (in-house) | FITC-conjugated Goat Anti-Rabbit IgG (H+L), (Jackson ImmunoResearch, Baltimore, USA) |
| RVFV | Mouse polyclonal antibodies (provided by Michele Bouloy, Pasteur Institute, Paris). | FITC-conjugated Rabbit Anti-Mouse Immunoglobulins, (DAKO Cytomation, Denmark) |
| DENV 1 | Mouse monoclonal to Dengue Virus E glycoprotein, (Abcam, Cambridge, UK) | FITC-conjugated Goat Anti-Mouse IgG, (Jackson ImmunoResearch, Baltimore, USA) |
| YFV | Mouse Monoclonal to Yellow Fever Virus, (Abcam, Cambridge, UK) | FITC-conjugated Goat Anti-Mouse IgG, (Jackson ImmunoResearch, Baltimore, USA) |
Primers and probes
| Virus | Oligomer | Sequence 5`to 3' |
|---|---|---|
| CCHFV | CCFM FP | TCACCTTAGAGGAGGACACTGAAGG |
| CCFM RP | CTCTTTTGAAAGAAAGTGTCATCACAATC | |
| CCHF M LNA | 6FAM - TGGTGT | |
| LASV | LAS FP | YAACTCTGCATTYTTCACATCCC |
| LAS RP | TGGGMAACCTAAGYTCACAGCA | |
| LAS P | 6FAM - ACCACTCCATCTCTCCCAGCC - TMR |
LNA Nucleotides in bold, IUB code used Y for C/T, M for A/C, dyes and quenchers used: 6FAM =, 6-Carboxyfluorescein BBQ = Black Berry Quencher, TMR = Tetramethylrhodamin
Quantitative detemination of virus titers
| Virus | EM particles/ml | PCR genomes/ml | Infectivity FFU/ml | log10 difference PCR to EM | log10 difference FFU to EM | log10 difference FFU to PCR |
|---|---|---|---|---|---|---|
| EBOZV Mayinga | 2.5 × 108 | 8.3 × 1010 ± 3.2 × 109 | 1.0 × 105 | +2 | -3 | -5 |
| EBOSV Maridi | 7.5 × 108 | 8.6 × 1010 ± 5.4 × 109 | 1.0 × 103 | +2 | -5 | -7 |
| EBOSV Boniface | 8.0 × 108 | 5.9 × 1010 ± 3.4 × 109 | 1.0 × 104 | +2 | -4 | -6 |
| MARV Ravn | 4.0 × 108 | 1.3 × 108 ± 1.8 × 106 | 1.0 × 105 | 0 | -3 | -3 |
| MARV Ozolin | 5.0 × 109 | 1.6 × 109 ± 1,1 × 108 | 1.0 × 106 | 0 | -3 | -3 |
| MARV Musoke | 3.0 × 109 | 5.8 × 108 ± 2.7 × 107 | 1.0 × 105 | -1 | -4 | -3 |
| LASV Josiah | 1.0 × 106 | 2.2 × 107 ± 4.7 × 106 | 1.0 × 104 | +1 | -2 | -3 |
| RVFV ZH548 | 2.5 × 109 | 2.9 × 1011 ± 4.3 × 109 | 1.0 × 106 | +2 | -3 | -5 |
| DENV-1 231 | 3.0 × 109 | 4.6 × 1010 ± 4.3 × 109 | 1.0 × 106 | +1 | -3 | -4 |
| YFV Asibi | 4.0 × 108 | 8.2 × 109 ± 1.7 × 108 | 1.0 × 108 | +1 | 0 | -1 |
| CCHFV 10200 | 2.5 × 107 | 1.0 × 106 ± 6.1 × 105 | 1.0 × 106 | +1 | -1 | -2 |
EM: calculated from 10 grid squares, qPCR: average and standard deviation of triplicate qPCR results (8 qPCR results for CCHFV), FFU: mean of three titrations.
Selected ratios of quantitative titer results
| Virus | particles/FFU | genomes/particle | particles/genome | genome/FFU |
|---|---|---|---|---|
| EBOZV Mayinga | 2.5 × 103 | 336 | 0.00 | 8.3 × 105 |
| EBOSV Maridi | 7.5 × 105 | 115 | 0.01 | 8.6 × 107 |
| EBOSV Boniface | 8.0 × 104 | 74 | 0.01 | 5.9 × 106 |
| MARV Ravn | 4.0 × 103 | 0.3 | 3.08 | 1.3 × 103 |
| MARV Ozolin | 5.0 × 103 | 0.3 | 2.98 | 1.6 × 103 |
| MARV Musoke | 3.0 × 104 | 0.2 | 5.10 | 5.8 × 103 |
| LASV Josiah | 100 | 22 | 0.05 | 2.2 × 103 |
| RVFV ZH548 | 2.5 × 103 | 119 | 0.01 | 2.9 × 107 |
| DENV 1 231 | 3.0 × 103 | 15 | 0.06 | 4.6 × 104 |
| YFV Asibi | 4 | 21 | 0.05 | 83 |
| CCHFV IbAR 10200 | 25 | 0.04 | 24 | 1 |
Figure 1Electron microscopic pictures of malformed CCHFV particles. Upper panel particles without glycoproteins in lipid membrane, lower panel: mixture of whole particles with glycoproteins and malformed particles without glycoproteins.